Page last updated: 2024-09-05

ly 353381 and Disease Exacerbation

ly 353381 has been researched along with Disease Exacerbation in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Buzdar, AU; Deshmane, V; Krishnamurthy, S; Melemed, AS; Peterson, P	1
Fabian, CJ; Kimler, BF	1

Reviews

1 review(s) available for ly 353381 and Disease Exacerbation

Article	Year
Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. Annals of the New York Academy of Sciences, 2001, Volume: 952 Topics: Aneuploidy; Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Clinical Trials, Phase II as Topic; Cyclooxygenase Inhibitors; Disease Progression; Eflornithine; Endpoint Determination; Enzyme Inhibitors; Estrogens; Female; Fenretinide; Gonadotropin-Releasing Hormone; Humans; Hyperplasia; Isoflavones; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Polyamines; Precancerous Conditions; Protein-Tyrosine Kinases; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Uterine Neoplasms	2001

Article

Year

Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.

Annals of the New York Academy of Sciences, 2001, Volume: 952

Topics: Aneuploidy; Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Clinical Trials, Phase II as Topic; Cyclooxygenase Inhibitors; Disease Progression; Eflornithine; Endpoint Determination; Enzyme Inhibitors; Estrogens; Female; Fenretinide; Gonadotropin-Releasing Hormone; Humans; Hyperplasia; Isoflavones; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Polyamines; Precancerous Conditions; Protein-Tyrosine Kinases; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Uterine Neoplasms

2001

Trials

1 trial(s) available for ly 353381 and Disease Exacerbation

Article	Year
Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-01, Volume: 25, Issue:31 Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Piperidines; Postmenopause; Receptors, Steroid; Survival Analysis; Tamoxifen; Thiophenes; Time Factors; Treatment Failure	2007

Article

Year

Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-01, Volume: 25, Issue:31

Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Piperidines; Postmenopause; Receptors, Steroid; Survival Analysis; Tamoxifen; Thiophenes; Time Factors; Treatment Failure

2007